Cassady Schiller Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Cassady Schiller Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$367	Buy	+18	New	+$461	﹤0.01%	1024

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cassady Schiller Wealth Management's DNLI Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Denali Therapeutics (DNLI) in Q4 2024: 18 shares worth $367. The stake represents ﹤0.01% of the portfolio and ranks #1024 among its holdings.

223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

Cassady Schiller Wealth Management held 18 shares of Denali Therapeutics worth $367 as of Q4 2024.
Denali Therapeutics was a new Cassady Schiller Wealth Management position in Q4 2024.
Denali Therapeutics made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #1024 holding.
223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.